New drug cocktail aims to fight advanced cancers

NCT ID NCT01334073

Completed Disease control Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a daily combination of two oral drugs, axitinib and everolimus, in 19 people with advanced solid tumors, particularly kidney cancer. The main goal was to find the safest dose by monitoring side effects in the first month. Researchers also tracked how well the tumors responded to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: axitinib plus everolimus (two oral drugs taken daily)
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced solid tumors, especially kidney cancer, by shrinking tumors or slowing their growth.
What could go wrong: This is a very early Phase 1 trial with only 19 participants, focused on finding a safe dose. The combination may cause significant side effects and may not prove effective in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer hepatocellular carcinoma neoplasm renal cell adenocarcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, RENAL CELL MALIGNANT ADVANCED SOLID TUMORS

Contacts and locations

Locations

Professeur Alain RAVAUD

Bordeaux, 33000, France
Professeur Jean-Pierre DELORD

Toulouse, 31000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.